Stages III-IV Gastric Cancer


Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for... Continue Reading

Opdivo® Improves Survival in Advanced Stomach Cancer (November 30, 2016)

The immune-stimulating agent Opdivo® (nivolumab) appears to significantly improve overall survival among patients with advanced stomach cancer for which no standard treatment options exist. Opdivo is... Continue Reading

Novel Antibody Improves Survival in Advanced Stomach Cancer (June 28, 2016)

The novel agent, IMAB362, which stimulates the immune system to attack a certain protein expressed by many stomach cancer cells, has demonstrated a significant improvement in survival compared to standard... Continue Reading

IMAB362 Leads to Longer Remission and Better Survival in Gastric Cancer (June 6, 2016)

The results of a novel treatment for gastric cancer with the investigational antibody IMAB362 were released at the American Society of Clinical Oncology (ASCO) this week. IMAB362 led to extended remissions... Continue Reading

Lynparza Improves Overall Survival in High-Risk Gastric Cancer (September 9, 2015)

The combination of LynparzaTM (olaparib), and paclitaxel improves overall survival relative to paclitaxel alone in patients with metastatic gastric cancer and low or undetectable levels of a DNA damage... Continue Reading

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs (August 10, 2015)

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract or lungs. The trial... Continue Reading

Reolysin® Receives FDA Designation for Gastric Cancer (May 14, 2015)

The U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) to Reolysin®, an injectable cancer-killing virus, for the treatment of gastric cancer. Oncolytics Biotech® Inc.... Continue Reading

U.S. FDA Issues Warning about Certain Type of Endoscope (February 20, 2015)

The U.S. Food and Drug Administration (FDA) has issued a Safety Communication about a certain type of endoscope­—specifically the device used in endoscopic retrograde cholangiopancreatography (ERCP).... Continue Reading

AFCR-supported International Collaborative Research Maps Mutations in Gastric Cancer, Paving the Way for Personalized Medicine (February 17, 2015)

CancerConnect News: An international team of research scientists has revealed new genetic insights that could change the way oncologists treat gastric cancer – the fourth most common cancer and the second... Continue Reading

AMG 337 MET Inhibitor Produces Impressive, Rapid Response in Gastric and Esophageal Cancers (February 12, 2015)

AMG 337 is a novel small-molecule MET inhibitor that appears to show promise in the treatment of MET-amplified gastroesophageal junction, gastric, and esophageal cancers. MET inhibitors are a class of... Continue Reading

FDA Approves Cyramza™ in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (November 13, 2014)

The U.S. Food and Drug Administration(FDA) has approved Cyramza™ (ramucirumab) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction... Continue Reading

New Online Support Group for People Affected by Gastrointestinal Conditions: IBS, Crohn’s, UC, GERD, Cancer and More (August 14, 2014)

Are you suffering from a gastrointestinal (GI) tract condition? You are not alone! TheGIConnection is now available for patients, caregivers, and health consumers as an up to date online information resource... Continue Reading

Apatinib Prolongs Survival in Advanced Gastric Cancer (June 26, 2014)

Apatinib significantly improved overall survival according to the results of a phase III study presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Gastric cancer... Continue Reading

Ramucirumab Plus Paclitaxel Improves Survival in Metastatic Gastric Cancer (February 21, 2014)

Ramucirumab significantly improved both progression-free and overall survival, when added to paclitaxel in second-line therapy for metastatic gastric cancer, according to the results of a study presented... Continue Reading

Ramucirumab Prolongs Survival in Advanced Gastric Cancer (October 28, 2013)

The investigational targeted agent ramucirumab prolongs survival in patients with advanced gastric cancer after standard treatments have failed, according to the results of a study published early online... Continue Reading

Second-Line Docetaxel Improves Survival in Esophageal and Gastric Cancer (April 3, 2013)

Second-line treatment with docetaxel improves overall survival of patients with advanced esophageal and gastric cancer, according to the results of a study presented at the 2013 Gastrointestinal Cancers... Continue Reading

Adjuvant Radiochemotherapy Demonstrates Benefit in Gastric Cancer (September 25, 2012)

Adjuvant radiochemotherapy provides strong and persistent benefit in patients who have undergone curative gastric resection, according to the long-term results of a study published in the Journal of Clinical... Continue Reading

Factors Affecting Quality of Life at the End of Life (July 20, 2012)

For people with advanced cancer, quality of life at the end of life—sometimes referred to as “a good death”—may have less to do with medical treatment and more to do with a therapeutic alliance... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS